Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators.
Pignata S, et al. Among authors: natale d, d arco am.
BMC Cancer. 2006 Aug 1;6:202. doi: 10.1186/1471-2407-6-202.
BMC Cancer. 2006.
PMID: 16882344
Free PMC article.
Clinical Trial.